IP Library Granted Patent US 8,476,069
Granted Patent B2
US 8,476,069 · App. 13/339,225 · Granted Jul 2, 2013

Cells useful for immuno-based botulinum toxin serotype A activity assays

Inventors: Hong Zhu (San Diego, CA); Joanne Wang (Irvine, CA); Birgitte P. S. Jacky (Long Beach, CA); D. Dianne Hodges (Tustin, CA); Fernandez-Salas Ester (Fullerton, CA)
Assignee: Allergan, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,476,069
App. No.
13/339,225
Granted
Jul 2, 2013
Kind
B2
Abstract

The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.

Claims (8)

1. An established single cell derived clonal cell line from a parental SiMa cell line DSMZ ACC 164 comprising cells susceptible to intoxication by botulinum toxin type A (BoNT/A),

wherein the cells exhibit at least a 1.5-fold increase in mRNA expression levels after differentiation in the genes CD9, ENC1, Gβγ, GNAI1, GNG11, GNG12, GPSM2, ITGA6, JNK, KCNJ4, MSN, MYRIP, NXPH1, STK17A, TRAF4, TSPAN, TSPAN4 and VAV3 relative to the mRNA expression levels of each of these genes in cells from a 2D6 derived from the parental SiMa cell line DSMZ ACC 164; and,

wherein the cells exhibit at least a 1.5-fold decrease in mRNA expression levels after differentiation in the genes CNGA3, HIST1H3E and PTGS1 as compared to the mRNA expression levels of each of these genes in cells from the 2D6 cell line; and,

wherein the clonal cell line comprises cells susceptible to BoNT/A intoxication by about 100 pM or less of a BoNT/A.

2. The established clonal cell line of claim 1 , wherein the cells exhibit at least a 2.0-fold difference in gene expression levels of at least one gene as compared to the expression levels of the gene in cells from the 2D6 cell line.

3. The established clonal cell line of claim 1 , wherein the cells exhibit at least a 3.0-fold difference in gene expression levels of at least one gene as compared to the expression levels of the gene in cells from the 2D6 cell line.

4. The established clonal cell line of claim 1 , wherein the cells exhibit at least a 4.0-fold difference in gene expression levels of at least one gene as compared to the expression levels of the gene in cells from the 2D6 cell line.

5. The established clonal cell line of claim 1 , wherein the cell from an established clonal cell line exhibits about 100 pM or less of a BoNT/A intoxication for at least 5 or more cell passages.

Continuity (3)
Division 12722801 · Mar 12, 2010
Provisional Application 61160199 · Mar 13, 2009
Related Publication 20120156775A1 · Jun 21, 2012